Phoenix 8.0

Phoenix 8.0

Phoenix PK/PD Modeling and Simulation Software Phoenix extends the winning formula of WinNonlin by combining its trusted algorithms with an easy-to-use graphical user interface and the additional tools needed to support more advanced analysis, such as population PK/PD modeling with Phoenix NLME and in vitro-in vivo correlation with the IVIVC Toolkit. The Phoenix Workbench leverages […]

Read More
Topics:

The Phoenix Reporter

A Compendium of Insightful Information for Our Phoenix Community, Vol. 3 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.0, the newest version of our PK/PD software: Phoenix WinNonlin 8.0—Taking […]

Read More
Topics:

Phoenix Modeling Language School

Learn How to Build Custom PK and PK/PD Models Phoenix WinNonlin® uses Phoenix Modeling Language (PML) to encode pharmacokinetic (PK) and Pharmacodynamic (PD) models. Although most models can be built using the graphical user interface (GUI) in Phoenix, there are some models that require custom coding with PML. Certara has launched a series of interactive […]

Read More
Topics:

PK/PD Modeling and Simulation

Phoenix: The Most Advanced, Intuitive, and Widely-used Software for Pharmacokinetic (PK), Pharmacodynamic (PD), and Toxicokinetic (TK) Modeling and Simulation Phoenix®, the industry’s premier PK/PD modeling and simulation software workbench, is used by over 6,000 scientists in 60 countries at nearly 2,000 institutions, including the top 50 global pharmaceutical companies. Regulatory agencies, including 11 divisions of the US […]

Read More
Topics:

PK/PD Analysis

PK/PD Support for Drug Approvals Pharmacometrics: From “nice to have” to “must have” technology Model informed drug development and discovery—which includes both top-down pharmacokinetic/pharmacodynamic (PK/PD) modeling and bottom-up, mechanistic approaches―continues to profoundly impact drug development by informing key decisions and labeling. Key benefits of this approach include: Making data-driven decisions at all stages of drug […]

Read More
Topics:
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog